Review article · 2022 · Open access
Alzheimer's disease drug development pipeline: 2022
Alzheimer s & Dementia Translational Research & Clinical Interventions, 8(1), e12295 · Published 1 January 2022 · DOI 10.1002/trc2.12295
In brief
“Alzheimer's disease drug development pipeline: 2022” is a 2022 review article by Jeffrey L. Cummings and 6 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 733 citations as of 15 November 2026, which puts it in the top 7% of works published in 2022 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.
- Citations
- 733
- Most cited in
- 2023 (235)
- Field-weighted impact
- 18.00
- References
- 39
- Authors
- 7
Abstract
Introduction: Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD. Methods: We searched the governmental website clinicaltrials.gov where are all clinical trials conducted in the United States must be registered. We used artificial intelligence (AI) and machine learning (ML) approaches to ensure comprehensive detection and characterization of trials and drugs in development. We use the Common Alzheimer's Disease Research Ontology (CADRO) to classify drug targets and mechanisms of action of drugs in the pipeline. Results: As of January 25, 2022 (index date for this study) there were 143 agents in 172 clinical trials for AD. The pipeline included 31 agents in 47 trials in Phase 3, 82 agents in 94 trials in Phase 2, and 30 agents in 31 trials in Phase 1. Disease-modifying therapies represent 83.2% of the total number of agents in trials; symptomatic cognitive enhancing treatments represent 9.8% of agents in trials; and drugs for the treatment of neuropsychiatric symptoms comprise 6.9%. There is a diverse array of drug targets represented by agents in trials including nearly all CADRO categories. Thirty-seven percent of the candidate agents in the pipeline are repurposed drugs approved for other indications. A total of 50,575 participants are needed to fulfill recruitment requirements for all currently active clinical trials. Discussion: The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. Advances in drug design, outcome measures, use of biomarkers, and trial conduct promise to accelerate the delivery of new and better treatments for patients with AD. Highlights: There are 143 drugs in the current Alzheimer's disease (AD) drug development pipeline.Disease-modifying therapies represent 83.2% of the candidate treatments.Current trials require 50,575 participants who will donate 3,878,843 participant-weeks to clinical trials.The biopharmaceutical industry sponsors 50% of all clinical trials including 68% of Phase 3 trials.Sixty-three percent of Phase 3 trials and 46% of Phase 2 trials include non-North American clinical trial site locations indicating the global ecosystem required for AD drug development.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cummings, J. L., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Cacho, J. R. F., & Taghva, K. (2022). Alzheimer's disease drug development pipeline: 2022. Alzheimer s & Dementia Translational Research & Clinical Interventions, 8(1), e12295. https://doi.org/10.1002/trc2.12295
MLA 9
Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2022.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 8, no. 1, 2022, p. e12295. https://doi.org/10.1002/trc2.12295.
Chicago
Cummings, Jeffrey L., Garam Lee, Pouyan Nahed, Mina Esmail Zadeh Nojoo Kambar, Kate Zhong, Jorge Ramón Fonseca Cacho, and Kazem Taghva. 2022. “Alzheimer's disease drug development pipeline: 2022.” Alzheimer s & Dementia Translational Research & Clinical Interventions 8 (1): e12295. https://doi.org/10.1002/trc2.12295.
Harvard
Cummings, J. L. et al. (2022) ‘Alzheimer's disease drug development pipeline: 2022’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 8(1), p. e12295. doi:10.1002/trc2.12295.
IEEE
J. L. Cummings et al., “Alzheimer's disease drug development pipeline: 2022,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 8, no. 1, p. e12295, 2022, doi: 10.1002/trc2.12295.
BibTeX
@article{cummings2022alzheimer,
title = {{Alzheimer's disease drug development pipeline: 2022}},
author = {Cummings, Jeffrey L. and Lee, Garam and Nahed, Pouyan and Kambar, Mina Esmail Zadeh Nojoo and Zhong, Kate and Cacho, Jorge Ramón Fonseca and Taghva, Kazem},
journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
year = {2022},
volume = {8},
number = {1},
pages = {e12295},
doi = {10.1002/trc2.12295},
url = {https://doi.org/10.1002/trc2.12295}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2018 | 2 | |
| 2020 | 3 | |
| 2021 | 12 | |
| 2022 | 78 | |
| 2023 | 235 | |
| 2024 | 193 | |
| 2025 | 132 | |
| 2026 | 78 |
Its field-weighted citation impact is 18.00: it has been cited 18.00 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- drug development pipeline
- clinical trials
- disease-modifying therapy
- symptomatic treatment
- neuropsychiatric symptoms
- drug repurposing
- therapeutic target
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Cummings, J. L., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Cacho, J. R. F., & Taghva, K. (2022). Alzheimer's disease drug development pipeline: 2022. Alzheimer s & Dementia Translational Research & Clinical Interventions, 8(1), e12295. https://doi.org/10.1002/trc2.12295
How many times has this paper been cited?
733 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.
Who wrote this paper?
Jeffrey L. Cummings, Garam Lee, Pouyan Nahed, Mina Esmail Zadeh Nojoo Kambar, Kate Zhong, Jorge Ramón Fonseca Cacho, Kazem Taghva.
What is the DOI of this paper?
10.1002/trc2.12295. The permanent link is https://doi.org/10.1002/trc2.12295.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.